Venus Concept Inc. (VERO): Price and Financial Metrics
VERO Price/Volume Stats
| Current price | $2.01 | 52-week high | $8.25 |
| Prev. close | $1.96 | 52-week low | $1.51 |
| Day low | $1.90 | Volume | 2,000 |
| Day high | $2.01 | Avg. volume | 20,083 |
| 50-day MA | $1.91 | Dividend yield | N/A |
| 200-day MA | $2.97 | Market Cap | 11.11M |
VERO Stock Price Chart Interactive Chart >
VERO Stock Summary
- VENUS CONCEPT INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 1.39% of US listed stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 60.72 for VENUS CONCEPT INC; that's greater than it is for 99.19% of US stocks.
- In terms of volatility of its share price, VERO is more volatile than 97.3% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to VENUS CONCEPT INC, a group of peers worth examining would be EML, ORGO, BRC, HUN, and TNC.
- VERO's SEC filings can be seen here. And to visit VENUS CONCEPT INC's official web site, go to www.venusconcept.com.
VERO Valuation Summary
- In comparison to the median Healthcare stock, VERO's price/sales ratio is 94.74% lower, now standing at 0.1.
- Over the past 72 months, VERO's price/earnings ratio has gone up 12.9.
Below are key valuation metrics over time for VERO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VERO | 2023-09-22 | 0.1 | -1.7 | -0.3 | -2.4 |
| VERO | 2023-09-21 | 0.1 | -1.6 | -0.3 | -2.4 |
| VERO | 2023-09-20 | 0.1 | -1.8 | -0.3 | -2.5 |
| VERO | 2023-09-19 | 0.1 | -1.9 | -0.3 | -2.5 |
| VERO | 2023-09-18 | 0.1 | -1.8 | -0.3 | -2.5 |
| VERO | 2023-09-15 | 0.1 | -1.6 | -0.3 | -2.4 |
VERO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VERO has a Quality Grade of C, ranking ahead of 56.31% of graded US stocks.
- VERO's asset turnover comes in at 0.629 -- ranking 64th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows VERO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.629 | 0.676 | -0.148 |
| 2021-03-31 | 0.567 | 0.666 | -0.233 |
| 2020-12-31 | 0.508 | 0.659 | -0.503 |
| 2020-09-30 | 0.937 | 0.703 | -0.500 |
| 2020-06-30 | 1.031 | 0.701 | -0.667 |
| 2020-03-31 | 1.225 | 0.694 | -0.875 |
VERO Price Target
For more insight on analysts targets of VERO, see our VERO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.55 | Average Broker Recommendation | 1.3 (Strong Buy) |
Venus Concept Inc. (VERO) Company Bio
Venus Concept Inc. (formerly Restoration Robotics, Inc.), a medical device company, develops and commercializes image-guided robotic systems in the United States and internationally. It offers ARTAS System, a physician-assisted robotic system that identifies and dissects hair follicular units directly from the scalp and creates recipient implant sites. The company was founded in 2002 and is based in San Jose, California.
Latest VERO News From Around the Web
Below are the latest news stories about VENUS CONCEPT INC that investors may wish to consider to help them evaluate VERO as an investment opportunity.
Venus Concept Receives 510(k) Clearance for the Venus Versa Pro System, Its New Multi-Application PlatformTORONTO, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its Venus Versa Pro System, the Company’s new multi-application platform, for a variety of aesthetic and cosmetic procedures. Venus Versa is a modular system based on a multi-application approach. It is customizable and upg |
Venus Concept Inc. to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceTORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference, which is being held virtually and in person at the Lotte New York Palace in New York, NY from September 11th-13th. Management’s presentation will be available on demand beginning on Monday, September 11th at 7:00 a.m. Eastern |
Venus Concept Inc.'s (NASDAQ:VERO) Shares Not Telling The Full StoryWith a price-to-sales (or "P/S") ratio of 0.1x Venus Concept Inc. ( NASDAQ:VERO ) may be sending very bullish signals... |
Venus Concept Announces Second Quarter of Fiscal Year 2023 Financial ResultsTORONTO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2023. Second Quarter 2023 Summary & Recent Progress: Company continues to execute against Transformational Plan Total revenue of $20.1 million, down $7.2 million, or 26%, year-over-yearCash system revenue represented approximately 74% of total systems and subscriptions |
Venus Concept Announces Establishment of Medical Advisory Board For AI.ME™ -Its Next Generation Robotic PlatformTORONTO, July 13, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the establishment of a medical advisory board for AI.ME, its next generation robotic platform. The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technology, AI.ME, which received its first 510(k) clearance fro |
VERO Price Returns
| 1-mo | 14.86% |
| 3-mo | 0.50% |
| 6-mo | -36.19% |
| 1-year | -69.05% |
| 3-year | -94.10% |
| 5-year | -99.97% |
| YTD | -58.13% |
| 2022 | -81.18% |
| 2021 | -1.73% |
| 2020 | -63.19% |
| 2019 | -95.25% |
| 2018 | -90.43% |
Loading social stream, please wait...